GlassScriptPhysician profile
Kenneth J Headen
NPI 1366654329
$9,472.66
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,664 · 2020: $3,481 · 2021: $809 · 2022: $223 · 2023: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $280 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $280.39 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,292.11 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $948.77 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $943.56 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $710.34 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $650.60 | 2019-2023 | Ingrezza |
| Lundbeck LLC | $509.78 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $494.79 | 2019-2021 | |
| Validus Pharmaceuticals LLC | $465.68 | 2019-2020 | |
| Alkermes, INC. | $456.83 | 2019-2023 | Aristada, Vivitrol, Lybalvi |
| Vanda Pharmaceuticals INC. | $264.49 | 2019-2021 | |
| Abbvie INC. | $190.57 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $188.64 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.10 | 2019-2021 | |
| Indivior INC. | $67.46 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $51.78 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $31.56 | 2019 | |
| Axsome Therapeutics, INC. | $18.98 | 2023 | Auvelity |
| Adlon Therapeutics L.P. | $14.11 | 2020 | |
| Shire North American Group INC | $14.01 | 2019 | |
| Noven Therapeutics, LLC | $12.51 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.97 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Headen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.